Leading glaucoma experts Drs. Jamie Brandt and Pradeep Ramulu join host Dr. Andrew Pouw to talk about the burden of overdiagnosis and overtreatment of mild glaucoma, and mitigation strategies both in the clinic and at the policy desk.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Host Dr. Amanda Redfern welcomes Dr. Sravanthi Vegunta, a pediatric and neuro-ophthalmologist, to explain how to select the right radiologic imaging when you suspect a neuro-ophthalmic disorder. Dr. Vegunta breaks down idiopathic intracranial hypertension (IIH), papilledema, optic neuritis, optic atrophy, third and fourth cranial nerve palsies, Horner syndrome, and nystagmus. 

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Drs. Himani Goyal and Rahul Tonk sit down with host Dr. Jay Sridhar to discuss various diets (e.g., plant-based and Mediterranean) and nutritional supplements in the context of corneal and retinal disease, focusing on how to advise patients given what we know and what's supported by evidence and other medical specialties.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Dr. Thomas Johnson sits down with host Dr. Andrew Pouw to share exciting developments in regenerative stem cell research that may one day cure glaucoma.

Learn more about Dr. Johnson's work in a recent presentation he delivered on behalf of the Glaucoma Foundation, and through the Retinal Ganglion Cell Repopulation, Stem Cell Transplantation, and Optic Nerve Regeneration (RReSTORe) Consortium. 

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Drs. Jason Comander and Rachel Huckfeldt join host Dr. Ben Young to review management considerations for patients with retinitis pigmentosa (RP). The discussion highlights the winding story of nutritional supplementation recommendations for vitamin A, and the importance of reanalyzing data behind established care patterns. While the latest findings confirm that vitamin E supplementation should still be avoided, they no longer support any generalized neuroprotective effect of high-dose vitamin A for RP. 

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Dr. Peter Quiros joins host Dr. Amanda Redfern to discuss the recent JAMA Ophthalmology article "The Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide," the first study to report a possible association between semaglutide (Wegovy, Ozempic, Novo Nordisk) and nonarteritic anterior ischemic optic neuropathy (NAION). Dr. Quiros provides an overview of what the study showed and what remains unknown, and how ophthalmologists should discuss these recent findings with their patients.

Check out the Semaglutide and NAION patient brochure, courtesy of the North American Neuro-Ophthalmology Society (NANOS), and available from www.nanosweb.org.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Host Dr. Andrew Pouw welcomes Drs. Aakriti Shukla, Mahsaw Mansoor, and Alan Robin to discuss the latest sustainability initiatives in the ophthalmic OR and clinic that reduce waste, economic costs, and environmental impact.

The participants gratefully acknowledge the joint support of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery, the inspiration from physicians at the Aravind Eye Hospital, and the following individuals for their commitments to sustainability in ophthalmology: David Chang, MD, Barbara Erny, MD, Cathleen McCabe, MD, David Palmer, MD, Emily Schehlein, MD, and Cassie Thiel, PhD.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Drs. Maura Di Nicola and Basil Williams join host Dr. Jay Sridhar to discuss the latest ongoing ocular oncology clinical trials for the treatment of uveal melanoma and associated complications of radiation therapy.

Their review begins with the DRCR Retina Network’s Protocol AL, which is studying the use of anti-VEGF agents or corticosteroids to reduce the occurrence of radiation retinopathy and consequent vision loss. Drs. Di Nicola and Williams also offer insights about the use of belzupacap sarotalocan (bel-sar) for early-stage choroidal melanoma (CoMpass trial), as well as adjuvant treatment with darovasertib, a protein kinase C inhibitor.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Drs. Emmanuel Chang and Eric Nudleman join host Dr. Ben Young to review Stickler syndrome, when to suspect, and how to diagnose this condition that can lead to significant systemic manifestations and severe vision loss. The panel also discusses the role and evidence for prophylactic treatments to reduce the rate of retinal detachment, which can occur in up to 65% of affected patients.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Host Dr. Jay Sridhar welcomes Dr. Gareth Lema to discuss his group's recent study published in Ophthalmology that quantified the amount of eye drop waste in ophthalmic clinics and the implications for practice. When handled appropriately, argues Dr. Lema, eye drops can be used until the FDA-regulated expiration date, and thus help reduce both their carbon footprint and costs while still providing safe and effective patient care.

Read more: Tan JM, Chen B, Vail D et al. Ophthalmic drop waste due to self-imposed use cessation dates. Ophthalmology. 2024, Jul 1:S0161-6420(24)00391-9.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.